1-20 of 34
Markus Hansson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Francesca Gay, Heinz Ludwig, Sonja Zweegman, Vladimir Maisnar, Maria Teresa Petrucci, Paolo Corradini, Francesca Patriarca, Angelo Belotti, Micol Quaresima, Mariella Grasso, Massimo Offidani, Laura Paris, Anna Marina Liberati, Markus Hansson, Heleen Visser-Wisselaar, Giulia Fumero, Renato Zambello, Paula F Ypma, Anna Pascarella, Niels Frost Andersen, Alexandra Croockewit, Mario Boccadoro, Michele Cavo
Journal: Blood
Blood (2024) 144 (Supplement 1): 674.
https://doi.org/10.1182/blood-2024-197908
Published: 2024
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, Maria Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig C. Hofmeister, Paula Rodriguez Otero, Maria Aranzazu Bermúdez, Thomas Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier De La Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Costa
Journal: Blood
Blood (2023) 142 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2023-180013
Published: 2023
Journal Articles

Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Andrew Spencer, Katrine Fladeland Iversen, Binod Dhakal, Maria Creignou, Jenny Chen, Ida H Hiemstra, Sieto Bosgra, Avani Badani, Esther C.W. Breij, Lauren K. Brady, A. Kate Sasser, Anders Malmberg, Henrik Gregersen, Markus Hansson, Annemiek Broijl, Maria-Victoria Mateos, Torben Plesner
Journal: Blood
Blood (2022) 140 (Supplement 1): 7320–7321.
https://doi.org/10.1182/blood-2022-159116
Published: 2022
Journal Articles

Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients

Ulf-Henrik Mellqvist, Qian Cai, Laura L Hester, Michael Grövdal, Jakob Börsum, Iffat Rahman, Eric M. Ammann, Markus Hansson
Journal: Blood
Blood (2022) 140 (Supplement 1): 5230–5231.
https://doi.org/10.1182/blood-2022-158629
Published: 2022
Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh
Journal: Blood
Blood (2022) 140 (Supplement 1): 4407–4408.
https://doi.org/10.1182/blood-2022-162738
Published: 2022
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 400–402.
https://doi.org/10.1182/blood-2022-159009
Published: 2022
Journal Articles

Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

Katarina Uttervall, Hareth Nahi, Muhammad Kashif, Konstantinos Lemonakis, Sara Rosengren, Janaki Brolin, Johan Lund, Markus Hansson
Journal: Blood
Blood (2022) 140 (Supplement 1): 12605–12606.
https://doi.org/10.1182/blood-2022-158801
Published: 2022
Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Michele Cavo, Francesca Gay, MD, Meral Beksac, MD, Meletios A Dimopoulos, Lucia Pantani, MD PhD, Maria Teresa Petrucci, Luca Dozza, MSc, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Elena Zamagni, Giuseppe A. Palumbo, MD PhD, Francesca Patriarca, Monica Galli, Vladimir Maisnar, MD PhD MBA, Markus Hansson, MD, Angelo Belotti, Ludek Pour, MD, Paula F Ypma, MD PhD, Mariella Grasso, Sandra Croockewit, MD, Massimo Offidani, Renato Zambello, Anna Marina Liberati, MD, Niels Frost Andersen, MD PhD, Annemiek Broyl, MD PhD, Rossella Troia, PharmD, Pellegrino Musto, Heinz Ludwig, MD, Anna Maria Morelli, MD, Roman Hajek, MD, Christoph Driessen, MD, Anders Waage, MD PhD, Peter Gimsing, DO, PhD, Ulf-Henrik Mellqvist, MD PhD, Thilo Zander, MD, Mario Boccadoro, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-137575
Published: 2020
Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Anders Waage, MD PhD, Valdas Peceliunas, MD, Fredrik Schjesvold, MDPhD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Mervi Putkonen, MD PhD, Kristina Carlson, MD, Einar Haukaas, MD, Marja Sankelo, MDPhD, Anu Partanen, MD PhD, Damian L. Szatkowski, MDPhDMSc, Markus Hansson, MD PhD, Anu Marttila, MD, Lucia Ahlberg, MD, Per Axelsson, MD, Birgitta Lauri, MD, Maija Helena Mikkola, MD, Conny Karlsson, MD, Johanna Abelsson, MD, Erik Ahlstrand, MD PhD, Anu Sikiö, MD, Monika Klimkowska, MD PhD, Reda Matuzeviciene, MD PhD, Mona Hoysaeter Fenstad, MD PhD, Sorella Ilveskero, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-138643
Published: 2020
Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, MD, Thierry Facon, MD, Saad Z. Usmani, MDMBBS,MBA, Torben Plesner, MD DSc, Robert Z. Orlowski, MDPhD, Cyrille Touzeau, Supratik Basu, Nizar J. Bahlis, MD, Hartmut Goldschmidt, MD, Michael E. O'Dwyer, MD, Christopher P. Venner, MD, Katja Weisel, MD, Cyrille Hulin, MD, Lionel Karlin, MD, Meir Preis, MD PhD, Annemiek Broyl, MD PhD, William Renwick, Markus Hansson, MD, Maria Krevvata, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-134847
Published: 2020
Journal Articles

Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma

Fredrik Schjesvold, Vincent Ribrag, MD, Paula Rodriguez-Otero, MD PhD, Pawel J. Robak, MDPhD, Markus Hansson, MD, Roman Hajek, Adrián Alegre Amor, MD PhD, Joaquin Martinez-López, Maika Onishi, Jorge D. Gallo, Aparna Raval, Sameer Deshpande, Vikram Malhi, Wan-Jen Hong, MD, Marc S. Raab, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135845
Published: 2020
Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Henrik Gregersen, MD PhD, Valdas Peceliunas, MD, Kari Remes, MD PhD, Fredrik H. Schjesvold, MD PhD, Niels Abildgaard, MD, Hareth Nahi, MD PhD, Niels Frost Andersen, MD PhD, Annette Juul Vangsted, MD PhD, Tobias Wirenfeldt Klausen, M.S., Carsten Helleberg, MD, Kristina Carlson, MD, Ulf Christian Frølund, MD, Per Axelsson, MD, Olga Stromberg, MD, Cecilie Hveding Blimark, PhD MD, Olle Linder, MD, Galina Tsykunova, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Nina Gulbrandsen
Journal: Blood
Blood (2019) 134 (Supplement_1): 601.
https://doi.org/10.1182/blood-2019-122141
Published: 2019
Journal Articles

Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark

Niels Abildgaard, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Pekka Anttila, MD, Mate Szilcz, Yuanjun Ma, Katrine Hass Rubin, Lill-Brith von Arx, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini, Anders Green
Journal: Blood
Blood (2019) 134 (Supplement_1): 5030.
https://doi.org/10.1182/blood-2019-121953
Published: 2019
Journal Articles

Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study

Markus Hansson, MD PhD, Niels Abildgaard, MD, Anders Waage, MD PhD, Pekka Anttila, MD, Anders Green, Katrine Hass Rubin, Lill-Brith von Arx, Mate Szilcz, Yuanjun Ma, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini
Journal: Blood
Blood (2019) 134 (Supplement_1): 5037.
https://doi.org/10.1182/blood-2019-121983
Published: 2019
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

Sonja Zweegman, MD PhD, Bronno van der Holt, Fredrik H. Schjesvold, MDPhD, Mark-David Levin, PhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria Berhardina Leijs, MD, Saskia Klein, MD, Damian L. Szatkowski, MDPhDMSc, A Broyl, MDPhD, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MD, Asta Svirskaite, Sonia Cunha, Markus Hansson, MD PhD, Pieter Sonneveld, MDPhD, Einar Haukaas, Niels Abildgaard, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 433.
https://doi.org/10.1182/blood.V130.Suppl_1.433.433
Published: 2017
Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Claudia A.M. Stege, MD, Bronno van der Holt, Ulf-Henrik Mellqvist, MD, Mark-David Levin, PhD, Morten Salomo, Niels Abildgaard, MD, Gerard Bos, MDPhD, Heleen Visser-Wisselaar, Markus Hansson, MD PhD, Annette van der Velden, MD, Wendy Deenik, MD, Astrid Gruber, MD PhD, Jules L.L.M. Coenen, MD, Torben Plesner, MD, Saskia Klein, MD, Bea Tanis, MD PhD, Damian L. Szatkowski, MDPhDMSc, Rolf Brouwer, MD PhD, Matthijs Westerman, MD, Maria Berhardina Leijs, MD, Harm Sinnige, Einar Haukaas, Klaas van der Hem, MD PhD, Marc Durian, MD, Vera Mattijssen, MD PhD, Peter Gimsing, DO, PhD, Niels WCJ Van De Donk, Marian Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3146.
https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146
Published: 2017
Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD
Journal: Blood
Blood (2016) 128 (22): 4414.
https://doi.org/10.1182/blood.V128.22.4414.4414
Published: 2016
Journal Articles

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Clinical Trials & Observations
Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Francesco Di Raimondo, Katja C. Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesus San-Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig, Enrique M. Ocio, Gareth Morgan, Neil Miller, Mathew Simcock, Teresa Peluso, Jennifer Herring, Lars Sternas, Mohamed H. Zaki, Philippe Moreau
Journal: Blood
Blood (2016) 128 (4): 497–503.
https://doi.org/10.1182/blood-2016-02-700872
Published: 2016
Journal Articles

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Clinical Trials & Observations
Sonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard M. J. Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, Wendy Deenik, Astrid Gruber, Juleon L. L. M. Coenen, Torben Plesner, Saskia K. Klein, Bea C. Tanis, Damian L. Szatkowski, Rolf E. Brouwer, Matthijs Westerman, M. (Rineke) B. L. Leys, Harm A. M. Sinnige, Einar Haukås, Klaas G. van der Hem, Marc F. Durian, E. (Vera) J. M. Mattijssen, Niels W. C. J. van de Donk, Marian J. P. L. Stevens-Kroef, Pieter Sonneveld, Anders Waage
Journal: Blood
Blood (2016) 127 (9): 1109–1116.
https://doi.org/10.1182/blood-2015-11-679415
Published: 2016
Includes: Supplemental data